Multivariable-adjusted analysis evaluating potential predictors of recorded outcomes
| Covariate at baseline | OH hospitalisation n=504 | Unexplained syncope hospitalisation n=524 | ||
| Adjusted HR (95% CI) | p Value | Adjusted HR (95% CI) | p Value | |
| Female gender | 0.82 (0.67 to 1.01) | 0.061 | 0.81 (0.66 to 0.98) | 0.033 |
| Mean BMI, 1-unit increase | 0.97 (0.94 to 1.00) | 0.025 | 1.03 (1.00 to 1.05) | 0.033 |
| Mean age, 1 year increase | 1.11 (1.08 to 1.12) | <0.001 | 1.07 (1.05 to 1.09) | <0.001 |
| Current cigarette smoking | 0.99 (0.77 to 1.26) | 0.93 | 1.10 (0.87 to 1.38) | 0.426 |
| Diabetes | 1.82 (1.23 to 2.70) | 0.003 | 1.20 (0.79 to 1.84) | 0.386 |
| Prevalent CVD | 1.30 (0.89 to 1.89) | 0.183 | 1.59 (1.14 to 2.23) | 0.007 |
| Prevalent cancer | 0.73 (0.48 to 1.11) | 0.147 | 0.75 (0.50 to 1.13) | 0.167 |
| Systolic BP, 10 mm Hg increase | 1.05 (0.99 to 1.10) | 0.099 | 1.06 (1.01 to 1.12) | 0.024 |
| ACE-inhibitor | 1.06 (0.65 to 1.73) | 0.828 | 0.80 (0.49 to 1.31) | 0.378 |
| Beta-blocker | 1.17 (0.87 to 1.58) | 0.293 | 0.92 (0.69 to 1.23) | 0.584 |
| Calcium channel blocker | 0.74 (0.48 to 1.14) | 0.177 | 1.10 (0.77 to 1.57) | 0.589 |
| Diuretic | 1.06 (0.74 to 1.53) | 0.741 | 1.77 (1.31 to 2.38) | <0.001 |
| AHT* | 1.14 (0.89 to 1.46) | 0.304 | 1.26 (1.00 to 1.59) | 0.050 |
*Excluding the four classes of antihypertensive drugs from the model.
AHT, antihypertensive treatment; BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; OH, orthostatic hypotension.